Please login to the form below

Not currently logged in
Email:
Password:

Akzo Nobel

This page shows the latest Akzo Nobel news and features for those working in and with pharma, biotech and healthcare.

Pharma news in brief

Akzo to spin off pharma unit. Dutch chemicals and drug group, Akzo Nobel has announced it plans to spin off its pharmaceutical business after full year net profits for 2005 rose ... said Akzo chief executive Hans Wijers.

Latest news

  • EMEA seeks SSRI warning

    Other medicines covered by the EMEA review included other Lilly products Cymbalta and Strattera, Lundbeck's Celexa and Lexapro, Pfizer's Zoloft, Wyeth's Effexor and Akzo Nobel's Remeron.

  • Xceleron and Organon sign microdose study agreement

    UK-based contract research organisation Xceleron has revealed a collaboration with Organon, the human healthcare business unit of Netherlands-based Akzo Nobel, on a three-compound human microdose study focusing on

  • Schering-Plough completes Organon BioSciences acquisition

    The US company paid approximately EUR 11bn in cash for the company, which used to be a subsidiary of Dutch chemicals giant, Akzo Nobel.

  • Schering-Plough sales double on statins

    Organon acquisition. S-P is in the middle of acquiring Akzo Nobel's Organon unit, which is the second-largest EU manufacturer of contraceptive pills, in order to diversify away from ... In March 2007, S-P announced it was going to purchase Akzo Nobel's

  • Organon and MRC sign up for antibody development programme

    The pharmaceutical unit of Dutch chemicals giant Akzo Nobel, Organon, has signed a collaborative agreement with MRC Technology in the UK to develop a humanised antibody for the treatment of certain

More from news
Approximately 0 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics